NBRVF Stock - Nabriva Therapeutics plc
Unlock GoAI Insights for NBRVF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $35.67M | $27.22M | $5.03M | $7.75M | $6.50M |
| Gross Profit | $7.09M | $14.07M | $3.44M | $7.68M | $6.50M |
| Gross Margin | 19.9% | 51.7% | 68.5% | 99.1% | 100.0% |
| Operating Income | $-55,490,000 | $-48,528,000 | $-66,126,000 | $-79,489,000 | $-114,375,000 |
| Net Income | $-57,185,000 | $-49,450,000 | $-69,484,000 | $-82,764,000 | $-114,780,000 |
| Net Margin | -160.3% | -181.7% | -1382.2% | -1068.2% | -1765.8% |
| EPS | $-21.32 | $-28.52 | $-135.23 | $-278.75 | $-564.91 |
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Visit WebsiteEarnings History & Surprises
NBRVFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Sep 5, 2024 | — | — | — | — |
Q2 2024 | Jun 3, 2024 | — | — | — | — |
Q4 2023 | Oct 18, 2023 | — | $-3.73 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-3.73 | — | — |
Q3 2023 | Aug 28, 2023 | — | $-2.72 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-7.32 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-4.21 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-4.38 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-5.03 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-5.89 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-5.27 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-7.24 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-13.23 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-27.66 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-22.38 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-34.23 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-61.47 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-71.77 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-59.19 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-74.82 | — | — |
Latest News
Frequently Asked Questions about NBRVF
What is NBRVF's current stock price?
What is the analyst price target for NBRVF?
What sector is Nabriva Therapeutics plc in?
What is NBRVF's market cap?
Does NBRVF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NBRVF for comparison